AACR 2024 | Treating AKT1/3-mutated solid tumors with temsirolimus in the TAPUR trial

Deepti Behl, MD, Sutter Sacramento Medical Center, Sacramento, CA, discusses findings from the Phase II Targeted Agent and Profiling Utilization Registry (TAPUR) basket study (NCT02693535), which aims to assess commercially available targeted agents in patients with advanced cancers. In one cohort, patients with AKT1/3 amplification or mutation were treated with temsirolimus, an AKT inhibitor. The primary objective, which was stable disease over 16 months, was not met. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.